COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,358 Articles (22,803 medRxiv, 8,555 bioRxiv)

Most recent first Previous |  Page 1646: Articles 16451-16460  | Next

Comparable environmental stability and disinfection profiles of the currently circulating SARS-CoV-2 variants of concern B.1.1.7 and B.1.351
Meister, T. L., Fortmann, J., Todt, D., Heinen, N., Ludwig, A., Brueggemann, Y., Elsner, C., Dittmer, U., Pfaender, S., Steinmann, E.
10.1101/2021.04.07.438820 — Posted: 2021-04-08 Discussion: Onsite
SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney
Francis, M., Goncin, U., Kroeker, A., Swan, C., Ralph, R., Lu, Y., Etzioni, A., Falzarano, D., Gerdts, V., Machtaler, S., Kindrachuk, J., Kelvin, A. A.
10.1101/2021.04.07.438843 — Posted: 2021-04-08
Mental health inequalities in healthcare, economic, and housing disruption during COVID -19: an investigation in 12 longitudinal studies
Di Gessa, G., Maddock, J., Green, M. J., Thompson, E. J., McElroy, E., Davies, H. L., Mundy, J., Stevenson, A. J., Kwong, A. S. F., Griffith, G. J., Katikireddi, S. V., Niedzwiedz, C. L., Ploubidis, G. B., Fitzsimons, E., Henderson, M., Silverwood, R. J., Chaturvedi, N., Breen, G., Steves, C. J., Steptoe, A., Porteous, D. J., Patalay, P.
10.1101/2021.04.01.21254765 — Posted: 2021-04-07
Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2
Deepak, P., Kim, W., Paley, M. A., Yang, M., Carvidi, A. B., El-Qunni, A. A., Haile, A., Huang, K., Kinnett, B., Leibeskind, M. J., Liu, Z., McMorrow, L. E., Paez, D., Perantie, D. C., Schriefer, R. E., Sides, S., Thapa, M., Gergely, M., Abushamma, S., Kelbert, M., Mitchell, L., Nix, B., Graf, J. D., Taylor, K. E., Chahin, S., Ciorba, M. A., Katz, P. A., Matloubian, M., O'Halloran, J. A., Presti, R. M., Wu, G. F., Whelan, S. P., Buchser, W. J., Gensler, L. S., Nakamura, M. C., Ellebedy, A. H., Kim, A. H.
10.1101/2021.04.05.21254656 — Posted: 2021-04-07 Discussion: Onsite
Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study
Hitchings, M., Ranzani, O. T., Torres, M. S. S., de Oliveira, S. B., Almiron, M., Said, R., Borg, R., Schulz, W. L., de Oliveira, R. D., da Silva, P. V., de Castro, D. B., Sampaio, V. d. S., de Albuquerque, B. C., Ramos, T. C. A., Fraxe, S. H. H., da Costa, C. F., Naveca, F. G., Siqueira, A. M., de Araujo, W. N., Andrews, J. R., Cummings, D. A. T., Ko, A. I., Croda, J.
10.1101/2021.04.07.21255081 — Posted: 2021-04-07 Discussion: Offsite
Increased vulnerability to SARS-CoV-2 infection among indigenous people living in the urban area of Manaus
Soares Pontes, G., de Melo Silva, J., Pinheiro-Silva, R., Nogueira Barbosa, A., Cardenes Santos, L., de Padua Quirino Ramalho, A., de Castro Alves, C. E., Furtado da Silva, D., Calheiros de Oliveira, L., Guimaraes da Costa, A., Bruno, A. C.
10.1101/2021.04.05.21254937 — Posted: 2021-04-07
New Zealand Emergency Department COVID-19 Preparedness Survey
Howard, M. J., Chambers, C., Mohr, N. M.
10.1101/2021.04.06.21253178 — Posted: 2021-04-07
COVID-19 vaccine hesitancy among individuals with cancer, autoimmune diseases, and other serious comorbid conditions
Tsai, R., Hervey, J., Hoffman, K. D., Wood, J., Novack, J., Johnson, J., Deighton, D. C., Loew, B., Goldberg, S. L.
10.1101/2021.04.06.21254014 — Posted: 2021-04-07
Making sense of non-randomized comparative treatment studies in times of Covid-19: A case study of tocilizumab
Owen, R. R. C., Qizilbash, N., Diaz, S. V., Vazquez, J. M. C., Pocock, S. J.
10.1101/2021.04.06.21254612 — Posted: 2021-04-07
Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients
Agha, M., Blake, M., Chilleo, C., Wells, A., Haidar, G.
10.1101/2021.04.06.21254949 — Posted: 2021-04-07 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).